Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
METOral Peptide
- Development stage
- Preclinical
- Lead developer
- Nanomerics
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
METOral Peptide is a preclinical-stage drug candidate being developed by Nanomerics for the treatment of diabetes. The candidate utilizes the company's proprietary METOral (Molecular Envelope Technology) platform, which is a nanoparticle-based delivery system designed to enable the oral administration of peptides. This technology aims to protect the peptide cargo from the harsh environment of the gastrointestinal tract and facilitate its transport across the intestinal epithelium into the bloodstream. While the specific identity of the peptide and its biological target have not been disclosed, the program represents an effort to transition injectable peptide treatments for diabetes into more patient-friendly oral formulations.
- Other names
- METOral Peptide platform
Beyond the preview
Go deeper on METOral Peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on METOral Peptide.